Current Report Articles
COVID-19 Two-Antibody Cocktail Therapy in Clinical Trial
Clinical Trial (July 3, 2020) – The Biomedical Advanced Research and Development Authority has announced that Regeneron, a BARDA partner, has begun the first clinical trials of REGN-COV2, its therapeutic two-antibody "cocktail" for COVID-19 patients. This treatment, developed with BARDA support, is designed to inhibit SARS-COV-2, the virus that causes COVID-19. The REGN-COV2 treatment contains two neutralizing monoclonal antibodies.
--Karen Braman